Cas:885520-22-9 4-chloro-1H-indol-6-amine manufacturer & supplier

We serve Chemical Name:4-chloro-1H-indol-6-amine CAS:885520-22-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

4-chloro-1H-indol-6-amine

Chemical Name:4-chloro-1H-indol-6-amine
CAS.NO:885520-22-9
Synonyms:6-amino-4-chloroindole
Molecular Formula:C8H7ClN2
Molecular Weight:166.60800
HS Code:2933990090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:41.81000
Exact Mass:166.03000
LogP:2.98470

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 6-amino-4-chloroindole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-amino-4-chloroindole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-amino-4-chloroindole Use and application,6-amino-4-chloroindole technical grade,usp/ep/jp grade.


Related News: U.S. drugmaker Gilead dominates the HIV market and it will keep up the pressure with fast-growing Biktarvy, which was approved early last year. 4-chloro-1H-indol-6-amine manufacturer ICIG companies currently employ more than 3,000 people and operate 15 manufacturing facilities in Europe and the United States. 4-chloro-1H-indol-6-amine supplier Darzalex has its own VRd combo trials, dubbed PERSEUS and CEPHEUS, which are testing a newly approved under-the-skin version of the J&J drug called Darzalex Faspro. The CEPHEUS trial appears to have just completed its primary analysis, according to a listing on ClinicalTrials.gov. 4-chloro-1H-indol-6-amine vendor f you’ve traveled in or transited through mainland China, you won’t be allowed into New Zealand unless you’re a New Zealand national. 4-chloro-1H-indol-6-amine factory AbbVie and Johnson & Johnson already boast three FDA-approved regimens for Imbruvica in newly diagnosed chronic lymphocytic leukemia (CLL). Now, the pair aims to add another to the drug’s label, one that could shorten the time patients need to stay on treatment.